Explore 3 Stock Ideas & Industry Insights Download Free Report

8082-737-676
Shopping Cart 0
countryflagUK
Login

MannKind Corp

Healthcare US MNKD

3.52USD
0.16(4.76%)

Last update at 2026-06-04T20:13:00Z

Day Range

3.343.53
LowHigh

52 Week Range

3.175.75
LowHigh

Fundamentals

  • Previous Close 3.36
  • Market Cap1260.82M
  • Volume3504163
  • P/E Ratio115.75
  • Dividend Yield-%
  • EBITDA35.82M
  • Revenue TTM224.60M
  • Revenue Per Share TTM0.84
  • Gross Profit TTM 42.27M
  • Diluted EPS TTM0.04

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Analyst Recommendations

Financials

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Income before tax -87.40000M -80.92600M -57.45800M -51.90300M -86.73500M
Minority interest - - - - -
Net income -112.16900M -91.79100M -57.24000M -59.72900M -86.97500M
Selling general administrative 37.72M 77.42M 59.04M 74.67M 79.72M
Selling and marketing expenses 53.75M - - - -
Gross profit 42.27M 36.59M 40.50M 35.06M 7.38M
Reconciled depreciation 9.11M 5.47M 3.33M 2.15M 2.86M
Ebit -68.92100M -53.48300M -24.78500M -46.51000M -80.99900M
Ebitda -66.51000M -53.61000M -24.59500M -46.43900M -78.14200M
Depreciation and amortization 2.41M -0.12700M 0.19M 0.07M 2.86M
Non operating income net other -8.27900M -18.70000M -5.22900M -1.00200M -0.70100M
Operating income -68.92100M -53.48300M -24.78500M -46.51000M -76.59500M
Other operating expenses 168.69M 128.93M 89.93M 109.55M 108.92M
Interest expense 24.77M 16.58M 9.47M 10.91M 9.44M
Tax provision 0.00000M 0.00000M -0.21800M 0.00000M 0.24M
Interest income 2.51M 0.11M 0.17M 1.00M 0.50M
Net interest income -22.25600M -16.46500M -9.30400M -9.90900M -8.93800M
Extraordinary items - - - - -
Non recurring - 0.11M 15.12M - -
Other items - - - - -
Income tax expense 24.77M 10.87M -0.21800M 7.83M 0.24M
Total revenue 99.77M 75.44M 65.14M 63.04M 27.86M
Total operating expenses 111.19M 90.07M 65.29M 81.57M 88.44M
Cost of revenue 57.50M 38.86M 24.64M 27.98M 20.48M
Total other income expense net -18.47900M -27.44300M -32.67300M -5.39300M 3.27M
Discontinued operations - - - - -
Net income from continuing ops -87.40000M -80.92600M -57.24000M -51.90300M -86.97500M
Net income applicable to common shares -87.40000M -80.92600M -57.24000M -51.90300M -86.97500M
Preferred stock and other adjustments - - - - -
Breakdown 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Type yearly yearly yearly yearly yearly
Date 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Total assets 475.20M 295.28M 321.16M 108.61M 93.72M
Intangible assets 1.07M 1.15M - - -
Earning assets - - - - -
Other current assets 34.35M 25.48M 3.48M 3.28M 3.21M
Total liab 721.37M 545.82M 530.51M 289.03M 284.25M
Total stockholder equity -246.16800M -250.53800M -209.34900M -180.41900M -190.52600M
Deferred long term liab - - - - -
Other current liab 53.48M 44.95M 33.59M 30.79M 23.30M
Common stock 2.70M 2.64M 2.52M 2.42M 2.12M
Capital stock 2.70M 2.64M 2.52M 2.42M 2.12M
Retained earnings -3229.40700M -3217.46900M -3130.06900M -3049.14300M -2991.90300M
Other liab - 105.18M 106.39M 95.95M 102.25M
Good will 1.93M 2.43M - - -
Other assets - 9.72M 5.19M 3.27M 2.18M
Cash 238.48M 69.77M 124.18M 67.00M 29.91M
Cash and equivalents - - - - -
Total current liabilities 104.12M 67.30M 48.35M 73.70M 65.62M
Current deferred revenue 9.09M 1.73M 0.83M 33.27M 32.50M
Net debt 143.90M 313.14M 258.56M 56.43M 91.51M
Short term debt 31.98M 9.56M 6.98M 4.06M 5.03M
Short long term debt 20.00M 9.56M 6.98M 4.06M 5.03M
Short long term debt total 382.38M 382.91M 382.74M 123.44M 121.41M
Other stockholder equity 2980.54M 2964.29M 2918.20M 2866.30M 2799.28M
Property plant equipment - 45.13M 36.61M 25.87M 26.78M
Total current assets 373.39M 234.90M 219.74M 79.48M 60.76M
Long term investments 7.16M 1.96M 56.62M - -
Net tangible assets - -254.11900M -209.34900M -180.41900M -190.52600M
Short term investments 56.62M 101.08M 79.93M 0.00000M 19.98M
Net receivables 15.40M 16.80M 4.99M 4.22M 3.51M
Long term debt 248.70M 368.00M 223.94M 5.00M 5.00M
Inventory 28.55M 21.77M 7.15M 4.97M 4.16M
Accounts payable 9.58M 11.05M 6.96M 5.58M 4.79M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income - - - - -0.01900M
Additional paid in capital - - - - -
Common stock total equity - 2.64M 2.52M 2.42M 2.12M
Preferred stock total equity - - - - -
Retained earnings total equity - -3217.46900M -3130.06900M -3049.14300M -2991.90300M
Treasury stock - - - - -
Accumulated amortization - - - - -
Non currrent assets other 2.74M 9.72M 8.19M 3.27M 6.19M
Deferred long term asset charges - - - - -
Non current assets total 101.81M 60.39M 101.42M 29.13M 32.97M
Capital lease obligations 3.92M 5.34M 1.04M 1.20M 2.51M
Long term debt total - 225.40M 223.94M 5.00M 5.00M
Breakdown 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Type yearly yearly yearly yearly yearly
Date 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Investments 20.92M 4.87M -137.07100M 20.00M -20.27800M
Change to liabilities - -1.57700M 15.14M 4.14M 2.90M
Total cashflows from investing activities - 4.87M -151.53700M 15.22M -22.84300M
Net borrowings - -0.01800M 177.68M 14.87M 63.70M
Total cash from financing activities 136.80M 21.41M 270.27M 49.85M 69.86M
Change to operating activities - -24.77000M -4.63000M -2.64400M -4.99600M
Net income -11.93800M -87.40000M -80.92600M -57.24000M -51.90300M
Change in cash 168.71M -54.41700M 57.02M 36.94M -41.46200M
Begin period cash flow 69.77M 124.18M 67.16M 30.22M 71.68M
End period cash flow 238.48M 69.77M 124.18M 67.16M 30.22M
Total cash from operating activities 33.91M -80.67900M -61.70900M -28.12800M -88.48300M
Issuance of capital stock 7.28M 19.79M 1.99M 23.66M 3.20M
Depreciation 5.80M 9.11M 5.47M 3.33M 2.15M
Other cashflows from investing activities - -20.34100M -3.00000M -3.98300M -20.27800M
Dividends paid - - 0.50M 14.87M 0.66M
Change to inventory -11.34700M -5.67000M -4.08100M -1.31400M -0.55800M
Change to account receivables 2.35M -11.80700M -0.77600M -0.70500M 0.50M
Sale purchase of stock -10.16200M 19.41M -0.49800M 0.68M 0.66M
Other cashflows from financing activities -8.34200M -0.06200M 99.71M 55.25M 122.93M
Change to netincome - 10.86M 24.84M 30.42M 0.87M
Capital expenditures 42.44M 7.59M 11.47M 4.78M 2.56M
Change receivables - -11.80700M -0.77600M -0.70500M 0.50M
Cash flows other operating - 8.80M -20.12000M -5.57500M -41.27100M
Exchange rate changes - - - - -
Cash and cash equivalents changes - -54.41700M 57.02M 36.94M -41.46200M
Change in working capital 14.63M -24.05400M -17.73000M -9.78000M -12.36000M
Stock based compensation 17.65M 13.45M 12.20M 6.51M 6.20M
Other non cash items 13.21M 8.22M 6.63M 18.40M -28.00300M
Free cash flow -8.53600M -88.26800M -73.17500M -32.91200M -91.04800M

Peer Comparison

Sector: Healthcare Industry: Biotechnology

Company Change (USD) Price (USD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to Revenue (x) Enterprise Value to EBITDA (x)
MNKD
MannKind Corp		 0.16 4.76% 3.52 115.75 37.88 5.65 - 5.55 53.54
NVO
Novo Nordisk A/S		 1.75 4.17% 43.75 41.58 31.15 2.13 32.99 2.11 4.70
NONOF
Novo Nordisk A/S		 1.78 4.22% 44.00 41.06 31.25 2.08 33.11 2.11 4.70
VRTX
Vertex Pharmaceuticals Inc		 13.40 3.13% 441.74 29.67 24.33 10.38 5.83 9.33 20.00
REGN
Regeneron Pharmaceuticals Inc		 9.78 1.58% 628.73 29.07 20.12 7.57 3.82 6.95 19.42

Reports Covered

Stock Research & News

View All

Profile

MannKind Corporation, a biopharmaceutical company, focuses on the development and commercialization of inhaled therapeutic products for endocrine and orphan lung diseases in the United States. It offers Afrezza, an inhaled insulin used to improve glycemic control in adults with diabetes, and the V-Go wearable insulin delivery device, which provides continuous subcutaneous infusion of insulin in adults. The company's product pipeline also includes Tyvaso DPI (Treprostinil), an inhalation powder for the treatment of pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease; MNKD-101, a nebulized formulation of clofazimine, for the treatment of severe chronic and recurrent pulmonary infections, including nontuberculous mycobacterial lung disease; MNKD-201, a dry-powder formulation of nintedanib, for the treatment of idiopathic pulmonary fibrosis (IPF). In addition, it has collaboration and license agreement with United Therapeutics Corporation for development, regulatory, and commercial activities of Tyvaso DPI; co-promotion agreement with Vertice Pharma to promote Thyquidity; and collaboration agreement with Thirona to evaluate the therapeutic for the treatment of pulmonary fibrosis. Further, the company has supply and distribution agreement with Biomm S.A. for the commercialization of Afrezza in Brazil; and license and distribution agreement with Cipla Ltd. for the marketing and distribution of Afrezza in India. MannKind Corporation was incorporated in 1991 and is headquartered in Danbury, Connecticut.

MannKind Corp

1 Casper Street, Danbury, CT, United States, 06810

Key Executives

Name Title Year Born
Dr. Michael E. Castagna Pharm.D. CEO & Director 1977
Mr. Steven B. Binder Chief Financial Officer 1963
Mr. Joseph Kocinsky M.B.A., M.S. Chief Technology Officer 1964
Dr. David B. Thomson Exec. VP, Gen. Counsel & Sec. 1967
Dr. Stuart A. Tross Ph.D. Chief People & Workplace Officer 1967
Mr. Thomas Hofmann M.D., Ph.D. Chief Scientific Officer NA
Ms. Rosabel Realica Alinaya VP of Investor Relations & Treasury 1961
Mr. John F. Bedard Sr. VP of Worldwide Regulatory Affairs 1950
Mr. James Patrick McCauley Jr., J.D., M.B.A. Chief Commercial Officer 1966
Ms. Lauren M. Sabella Executive VP & COO 1961

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

We use cookies to help us improve, promote, and protect our services. By continuing to use this site, we assume you consent to our Cookies Policy. For more information, read our Privacy Policy and Terms and Conditions